Clementia Pharmaceuticals, Inc.
http://clementiapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clementia Pharmaceuticals, Inc.
Ipsen Eyes Opportunity In Rare Liver Diseases With Albireo Buy
The French firm is paying a 104% premium plus contingent value rights of an additional $10 per share to get hold of AstraZeneca spin-off Albireo and its lead asset Bylvay, which is approved for progressive familial intrahepatic cholestasis and is showing promise in two other more lucrative indications.
RWE On The Runway: Trio Of Upcoming Approval Decisions Will Test US FDA’s Thinking On RWE For Efficacy
Real-world evidence provides external controls for bluebird bio’s eli-cel and Ipsen’s palovarotene, while Reata used RWE to address FDA concerns about the pivotal single-arm study of omaveloxolone. In the post-market, Intercept is gearing up to seek full approval of Ocaliva relying in part on claims database.
Ipsen Seeks Success Outside Big Pharma's Hunting Grounds
David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice